T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
Abstract Background Current guidelines consider T-DM1 the standard 2nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1st line treatment. Despite this, there are no prospective studies supporting this sequence. Methods We...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-09556-7 |
| _version_ | 1818253144041193472 |
|---|---|
| author | Claudia Omarini Federico Piacentini Isabella Sperduti Krisida Cerma Monica Barbolini Fabio Canino Cecilia Nasso Christel Isca Federica Caggia Massimo Dominici Luca Moscetti |
| author_facet | Claudia Omarini Federico Piacentini Isabella Sperduti Krisida Cerma Monica Barbolini Fabio Canino Cecilia Nasso Christel Isca Federica Caggia Massimo Dominici Luca Moscetti |
| author_sort | Claudia Omarini |
| collection | DOAJ |
| description | Abstract Background Current guidelines consider T-DM1 the standard 2nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1st line treatment. Despite this, there are no prospective studies supporting this sequence. Methods We performed a meta-analysis using real world data to determine the efficacy of T-DM1 after 1st line TP in HER2 positive MBC patients. We used a random-effect model to find differences in the rate of 1-year progression free survival (PFS) between TP pre-treated population and the EMILIA phase III pivotal trial. Results Seven studies were eligible. The meta-analysis showed a combined 1-year PFS risk difference for T-DM1 efficacy after TP in 2nd or more lines of -0.122, with lower and upper limits of -0.253 and 0.010, respectively (p = 0.07), with low heterogeneity among studies (I2 0.01%, p = 0.836). Considering the four studies on T-DM1 in 2nd line setting, 1-year PFS risk was -0.034 (95% CI -0.207 – 0,139; p = 0.701) (I2 0.01%, p = 0.91). Conclusion Overall, the efficacy of T-DM1 after TP seems to be similar to that previously reported in the EMILIA trial. In the second line setting, data are not mature enough to confirm T-DM1 efficacy in TP pre-treated population. |
| first_indexed | 2024-12-12T16:35:24Z |
| format | Article |
| id | doaj.art-e270a0a9d2444a0195b5a1e7d9648de1 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-12T16:35:24Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-e270a0a9d2444a0195b5a1e7d9648de12022-12-22T00:18:42ZengBMCBMC Cancer1471-24072022-06-012211710.1186/s12885-022-09556-7T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysisClaudia Omarini0Federico Piacentini1Isabella Sperduti2Krisida Cerma3Monica Barbolini4Fabio Canino5Cecilia Nasso6Christel Isca7Federica Caggia8Massimo Dominici9Luca Moscetti10Division of Medical Oncology, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Bio-Statistics, RCCS Regina Elena National Cancer InstituteDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDepartment of Medical and Surgical Sciences for Children & Adults, University Hospital of ModenaDivision of Medical Oncology, University Hospital of ModenaAbstract Background Current guidelines consider T-DM1 the standard 2nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1st line treatment. Despite this, there are no prospective studies supporting this sequence. Methods We performed a meta-analysis using real world data to determine the efficacy of T-DM1 after 1st line TP in HER2 positive MBC patients. We used a random-effect model to find differences in the rate of 1-year progression free survival (PFS) between TP pre-treated population and the EMILIA phase III pivotal trial. Results Seven studies were eligible. The meta-analysis showed a combined 1-year PFS risk difference for T-DM1 efficacy after TP in 2nd or more lines of -0.122, with lower and upper limits of -0.253 and 0.010, respectively (p = 0.07), with low heterogeneity among studies (I2 0.01%, p = 0.836). Considering the four studies on T-DM1 in 2nd line setting, 1-year PFS risk was -0.034 (95% CI -0.207 – 0,139; p = 0.701) (I2 0.01%, p = 0.91). Conclusion Overall, the efficacy of T-DM1 after TP seems to be similar to that previously reported in the EMILIA trial. In the second line setting, data are not mature enough to confirm T-DM1 efficacy in TP pre-treated population.https://doi.org/10.1186/s12885-022-09556-7HER2 positiveT-DM1PertuzumabTrastuzumab emtansineMetastatic breast cancer |
| spellingShingle | Claudia Omarini Federico Piacentini Isabella Sperduti Krisida Cerma Monica Barbolini Fabio Canino Cecilia Nasso Christel Isca Federica Caggia Massimo Dominici Luca Moscetti T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis BMC Cancer HER2 positive T-DM1 Pertuzumab Trastuzumab emtansine Metastatic breast cancer |
| title | T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis |
| title_full | T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis |
| title_fullStr | T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis |
| title_full_unstemmed | T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis |
| title_short | T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis |
| title_sort | t dm1 efficacy in trastuzumab pertuzumab pre treated her2 positive metastatic breast cancer patients a meta analysis |
| topic | HER2 positive T-DM1 Pertuzumab Trastuzumab emtansine Metastatic breast cancer |
| url | https://doi.org/10.1186/s12885-022-09556-7 |
| work_keys_str_mv | AT claudiaomarini tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT federicopiacentini tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT isabellasperduti tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT krisidacerma tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT monicabarbolini tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT fabiocanino tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT cecilianasso tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT christelisca tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT federicacaggia tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT massimodominici tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis AT lucamoscetti tdm1efficacyintrastuzumabpertuzumabpretreatedher2positivemetastaticbreastcancerpatientsametaanalysis |